AS1810722

AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research[1].

Product Specifications

CAS Number

[909561-15-5]

UNSPSC

12352005

Target

Cytochrome P450; STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/as1810722.html

Purity

98.10

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C(N)CN1CCN(C2=CC=C(NC3=NC=C4C(N(CC5=CC(F)=CC(F)=C5)C=C4)=N3)C=C2)CC1

Molecular Formula

C25H25F2N7O

Molecular Weight

477.51

References & Citations

[1]Shinya Nagashima, et al. Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem. 2009 Oct 1;17 (19) :6926-36.